Eur J Clin Pharmacol. 1984;27(4):379-91. doi: 10.1007/BF00549583.
The International Prospective Primary Prevention Study in Hypertension (IPPPSH), an international multicentre randomised double-blind trial, compares antihypertensive regimens containing a beta-blocker (oxprenolol) with regimens not containing a beta-blocker. The protocol was developed and the study started in 1977. 6,357 patients fulfilled the inclusion criteria and were enrolled by the end of 1980. Patients have been treated in 6 countries for 3 to 5 years by 288 general practitioner and hospital out-patient centres. Follow-up was finished at the end of 1983 when 25,651 years of patient treatment had been completed. At entry patients had a diastolic pressure of 100-125 mmHg with no clinical evidence of cerebrovascular or ischaemic heart disease (W.H.O. Stages I and II hypertension). The study was designed to examine three main objectives: any influence of oxprenolol on the incidence of myocardial infarction and sudden death compared with antihypertensive therapy not containing a beta-blocker; the influence of cerebrovascular accidents in the same two groups; a comparison of the antihypertensive effectiveness, and the subjective and objective tolerability of the regimens. This paper summarises the objectives and methodology, and examines randomisation between the two treatment groups at entry into the IPPPSH.
国际高血压前瞻性一级预防研究（IPPPSH）是一项国际多中心随机双盲试验，比较含β受体阻滞剂（氧烯洛尔）的降压方案与不含β受体阻滞剂的方案。该研究方案于1977年制定并启动。截至1980年底，有6357名患者符合纳入标准并被纳入研究。患者在6个国家的288个全科医生和医院门诊中心接受了3至5年的治疗。随访于1983年底结束，此时已完成25651年的患者治疗。入组时患者的舒张压为100 - 125 mmHg，无脑血管或缺血性心脏病的临床证据（世界卫生组织I期和II期高血压）。该研究旨在检验三个主要目标：与不含β受体阻滞剂的抗高血压治疗相比，氧烯洛尔对心肌梗死和猝死发生率的任何影响；两组中脑血管意外的影响；两种方案的降压效果以及主观和客观耐受性的比较。本文总结了目标和方法，并研究了IPPPSH入组时两个治疗组之间的随机化情况。
